Literature DB >> 10380122

Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.

E Chaput1, D Maubrou-Sanchez, F D Bellamy, A D Edgar.   

Abstract

One of the earliest steps of atherosclerotic plaque formation is an increase of circulating apolipoprotein B-containing lipoproteins which, after infiltrating the subendothelial space, undergo oxidative modification. Fenofibrate is an effective cholesterol- and triglyceride-lowering agent which has been shown to be beneficial in the treatment of atherosclerosis. Vitamin E, or alpha-tocopherol, is a powerful antioxidant which has been shown in a variety of studies to prevent lipoprotein peroxidation. The purpose of the present study was to investigate the effect of fenofibrate treatment, either alone or in combination with alpha-tocopherol, in reducing the susceptibility of lipoproteins to oxidative modification. Rats fed a normal diet were treated for up to 27 d with fenofibrate, either alone or in combination with equimolar doses of alpha-tocopherol. Combined VLDL (very low density lipoproteins) and LDL (low density lipoproteins) isolated after fenofibrate treatment were more resistant to copper-mediated oxidation, as assessed by conjugated diene formation. Lag time was prolonged up to 3.2-fold, while the maximal rate of diene production was significantly decreased by up to 2.2-fold. Treatment of rats with alpha-tocopherol alone at the selected dose had no significant effect on lag time, while the propagation rate was slightly decreased. Coadministration of fenofibrate with alpha-tocopherol prolonged the lag phase to a greater extent than fenofibrate alone, showing a synergistic interaction between the two compounds. Finally, the combination of fenofibrate and alpha-tocopherol was significantly more effective in modifying lipoprotein oxidation parameters than what was observed with alpha-tocopherol and bezafibrate or gemfibrozil. Thus, in addition to its well-established effects on lipoprotein concentrations and atherogenic parameters, fenofibrate reduces the susceptibility of VLDL and LDL to oxidative modification and exerts its action synergistically with alpha-tocopherol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10380122     DOI: 10.1007/s11745-999-0390-8

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  43 in total

1.  Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation.

Authors:  B Frei; J M Gaziano
Journal:  J Lipid Res       Date:  1993-12       Impact factor: 5.922

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling.

Authors:  V Kagan; E Serbinova; L Packer
Journal:  Biochem Biophys Res Commun       Date:  1990-06-29       Impact factor: 3.575

Review 4.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

5.  Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content.

Authors:  D L Tribble; J J van den Berg; P A Motchnik; B N Ames; D M Lewis; A Chait; R M Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

6.  Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene.

Authors:  P D Reaven; A Khouw; W F Beltz; S Parthasarathy; J L Witztum
Journal:  Arterioscler Thromb       Date:  1993-04

7.  Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging.

Authors:  M E Poynter; R A Daynes
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

8.  Effects of linoleate-enriched and oleate-enriched diets in combination with alpha-tocopherol on the susceptibility of LDL and LDL subfractions to oxidative modification in humans.

Authors:  P D Reaven; B J Grasse; D L Tribble
Journal:  Arterioscler Thromb       Date:  1994-04

9.  Ubiquinol prevents alpha-tocopherol consumption during liposome peroxidation.

Authors:  L Cabrini; C Stefanelli; D Fiorentini; L Landi
Journal:  Biochem Int       Date:  1991-03

10.  [How does fenofibrate exert its cholesterol-lowering effect? (author's transl)].

Authors:  E Wülfert
Journal:  Nouv Presse Med       Date:  1980-12-22
View more
  4 in total

Review 1.  PPARalpha in atherosclerosis and inflammation.

Authors:  Fokko Zandbergen; Jorge Plutzky
Journal:  Biochim Biophys Acta       Date:  2007-05-21

2.  Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats.

Authors:  Alaa El-Sisi; Sahar Hegazy; Eman El-Khateeb
Journal:  PPAR Res       Date:  2013-08-12       Impact factor: 4.964

3.  Biological evaluation of a siliconized analog of clofibrate (silafibrate) in rodents.

Authors:  Mojtaba Ziaee; Mohammad Ali Eghbal; Jafar Rahmani; Mohammad Ghaffarzadeh; Arash Khorrami; Alireza Garjani
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

Review 4.  Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.

Authors:  Hidekatsu Yanai; Hiroki Adachi; Mariko Hakoshima; Hisayuki Katsuyama
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.